Status:
UNKNOWN
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
Lead Sponsor:
Tehran University of Medical Sciences
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Behcet Syndrome
Uveal Disease
Eligibility:
All Genders
16-60 years
Phase:
NA
Brief Summary
The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions of Behcet's Disease treated with Methotrexate and Prednisolone
Detailed Description
To test in a randomized single blind control trial the efficacy of Etanercept in patients with posterior uveitis and/or retinal vasculitis of Behcet's disease treated with Methotrexate and prednisolon...
Eligibility Criteria
Inclusion
- Behcet's Disease according to the International Criteria for Behcet's disease (ICBD)
- Active posterior uveitis and/or retinal vasculitis
Exclusion
- Visual acuity inferior to 1/10 on Snellen chart
- Being under cytotoxic drugs or having received them in the past 2 months
- Not being able to follow the one year treatment and the regular follow ups
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00931957
Start Date
October 1 2010
End Date
October 1 2013
Last Update
November 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rheumatology Research Center, Behcet's Disease Unit (Shariati Hospital)
Tehran, Iran, 14114